13F Holdings
中文EN

KURA Kura Oncology, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1422143 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-35.0%
TTM EPS YoY-33.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-394.3%
Net margin-369.3%
FCF margin-112.4%
EBITDA margin-392.5%

Returns

ROE-224.9%
ROA-48.2%
ROIC (approx.)-389.8%
Asset turnover0.13x

Leverage & solvency

Liabilities / assets96.8%
Debt / equity0.55x
Current ratio3.60x
Interest coverage-227.12x

Cash quality & payout

Operating cash flow / net income0.29x
Accruals ratio-34.1%
Payout ratio—
Capex / revenue4.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$67.48M$53.88M$0——
R&D expense$251.07M$169.97M$115.23M$92.81M$84.72M
SG&A expense$119.98M$77.11M$50.57M$47.05M$46.54M
Operating income-$303.63M-$193.19M-$165.80M-$139.87M—
Interest expense$1.51M$1.62M$1.55M$229,000$414,000
Pretax income-$278.37M-$171.97M-$152.63M-$135.84M—
Income tax$297,000$2.02M$0$0$0
Net income-$278.67M-$173.98M-$152.63M-$135.84M-$130.47M
EBITDA-$302.60M-$192.35M-$164.96M-$139.11M—
EPS (basic)-3.18-2.02-2.08-2.03-1.97
EPS (diluted)-3.18-2.02-2.08-2.03-1.97
Weighted avg. shares (diluted)87.68M86.16M73.23M66.99M66.35M
Balance sheet
Cash & equivalents$149.10M$224.46M$37.32M$51.80M$90.67M
Short-term investments$518.14M$502.93M$386.64M$386.18M$427.29M
Receivables$8.80M$2.06M———
Inventory$413,000$0———
Current assets$708.66M$744.83M$432.48M$446.43M$522.29M
PP&E, net$7.86M$1.68M$1.86M$2.54M$2.67M
Total assets$738.36M$760.16M$448.94M$456.31M$534.05M
Current liabilities$116.97M$78.71M$35.26M$24.06M$22.45M
Short-term debt$0$2.61M———
Long-term debt$9.71M$6.92M$9.33M$9.16M—
Total debt$9.71M$9.52M$9.33M$9.16M—
Total liabilities$564.23M$346.52M$51.66M$36.03M$27.44M
Shareholders' equity$174.13M$413.64M$397.27M$420.28M$506.61M
Net debt-$139.39M-$214.94M-$27.99M-$42.64M—
Shares outstanding87.86M78.23M74.35M68.31M66.57M
Cash flow statement
Operating cash flow-$64.06M$134.32M-$124.82M-$110.06M-$104.55M
Capital expenditure$6.64M$472,000$168,000$626,000$1.15M
Free cash flow-$70.70M$133.84M-$124.99M-$110.69M-$105.70M
Investing cash flow-$13.10M-$101.59M$15.56M$32.63M-$126.83M
Financing cash flow$1.79M$154.42M$94.78M$38.56M-$3.44M
Depreciation & amortization$1.03M$848,000$849,000$759,000$558,000
Stock-based compensation$37.11M$33.90M$28.08M$26.32M$23.58M

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.